Company intelligence / Profile preview

HistoIndex

Ownership: Private
Development stage: Commercial

Overview

HistoIndex’s stain-free AI digital pathology solutions are actively used as secondary/exploratory endpoints in multiple FDA clinical trials for NASH/MASH. Their technology enables objective quantification of fibrosis and morphological features from preclinical through late-stage clinical development. The company’s platforms are widely adopted by academic centers, CROs, and biopharma partners globally.

Therapeutic areas: Metabolic DisordersOncologyGastroenterologyOther
Modalities: Device (AI digital pathology platform)Non-pharmacological therapy (diagnostic technology)Biophotonic imaging technology (Second Harmonic Generation)
Industry: Pathology

Partnerships

Bristol Myers SquibbGalectin TherapeuticsMadrigal PharmaceuticalsNovartisSagimet BiosciencesTakeda Pharmaceuticals

Beyond the preview

Go deeper on HistoIndex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HistoIndex.

Explore the full profile